Skip to main content

Table 4 Comparison of adverse events in the SD TGC group and HD TGC group

From: High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria

Abnormal laboratory measures (overall population)

Total population (n = 100)

SD TGC group (n = 54)

HD TGC group (n = 46)

P -value

BUN increase, n (%)

13 (13)

5 (9)

8 (17)

0.25

Impaired renal function, n (%)

19 (19)

11 (20)

8 (17)

0.8

Impaired hepatopancreatic function,n (%)

18 (18)

9 (17)

9 (19.5)

0.9

Impaired hematological function, n (%)

9 (9)

6 (11)

3 (6.5)

0.5

Abnormal laboratory measures (VAP subgroup)

Total population (n = 63)

SD TGC group (n = 30)

HD TGC group (n = 33)

P -value

BUN increase, n (%)

8 (13)

3 (10)

5 (15)

0.7

Impaired renal function, n (%)

12 (19)

6 (20)

6 (18)

1

Impaired hepatopancreatic function, n (%)

11 (17.5)

4 (13)

7 (21)

0.6

Impaired hematological function, n (%)

4 (6)

1 (3)

3 (9)

0.6

  1. Values are presented for all 100 patients with ventilator-associated pneumonia (VAP) and other VAP infections. All adverse events were graded 1 to 2. TGC treatment was interrupted in any patient with suspected severe adverse events.
  2. TGC, tigecycline; SD standard dose; HD, high dose; BUN, blood urea nitrogen.